Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.01), Zacks reports.
Kyverna Therapeutics Stock Performance
NASDAQ:KYTX traded down $0.07 during mid-day trading on Monday, hitting $1.93. The company had a trading volume of 408,909 shares, compared to its average volume of 436,781. The firm has a market cap of $83.32 million and a P/E ratio of -0.56. Kyverna Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $25.84. The business's fifty day moving average is $2.81 and its two-hundred day moving average is $4.08.
Institutional Trading of Kyverna Therapeutics
An institutional investor recently raised its position in Kyverna Therapeutics stock. Bank of America Corp DE boosted its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 41.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,788 shares of the company's stock after purchasing an additional 6,400 shares during the quarter. Bank of America Corp DE owned 0.05% of Kyverna Therapeutics worth $81,000 as of its most recent SEC filing. 18.08% of the stock is currently owned by institutional investors.
Kyverna Therapeutics Company Profile
(
Get Free Report)
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Read More
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
